| 1 |
33581505 | Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma. | 2021 Apr |
1 |
| 2 |
33878513 | CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells. | 2021 Jul |
1 |
| 3 |
32379457 | Hyaluronidase Coated Molecular Envelope Technology Nanoparticles Enhance Drug Absorption via the Subcutaneous Route. | 2020 Jul 6 |
1 |
| 4 |
28303669 | Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations. | 2017 Oct |
1 |
| 5 |
26032687 | Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition. | 2016 Feb |
1 |
| 6 |
26957440 | CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. | 2016 Jun |
1 |
| 7 |
25573383 | A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. | 2015 Apr 1 |
3 |
| 8 |
25940539 | Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. | 2015 Apr 20 |
2 |
| 9 |
24366214 | Determination of CUDC-101 in rat plasma by liquid chromatography mass spectrometry and its application to a pharmacokinetic study. | 2014 Mar |
3 |
| 10 |
25107918 | Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. | 2014 Oct 1 |
1 |
| 11 |
25450670 | Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2. | 2014 Dec 15 |
4 |
| 12 |
23536719 | Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. | 2013 Jun |
4 |
| 13 |
20143778 | Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. | 2010 Mar 11 |
2 |
| 14 |
20388807 | CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. | 2010 May 1 |
5 |